Ultragenyx Pharmaceutical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RARE research report →
Range $16 – $39
Price Chart
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets.
- CEO
- Emil D. Kakkis
- IPO
- 2014
- Employees
- 1,371
- HQ
- Novato, CA, US
Get TickerSpark's AI analysis on RARE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.68B
- P/E
- -3.22
- Fwd P/E
- 214.99
- PEG
- -0.26
- P/S
- 2.33
- P/B
- -4.53
- EV/EBITDA
- -6.56
- Div Yield
- 0.00%
- Gross Margin
- 82.88%
- Op Margin
- -64.11%
- Net Margin
- -71.78%
- ROE
- 213.22%
- ROIC
- -52.70%
Latest fiscal year · YoY change
- Revenue
- $673.00M+20.1%
- Gross Profit
- $564.00M+16.6%
- Op Income
- $-535,000,000
- Net Income
- $-575,000,000-1.0%
- EPS
- $-5.83+7.3%
- OCF Growth
- -12.5%
- FCF Growth
- -11.9%
- 52W High
- $39.89
- 52W Low
- $12.73
- 50D MA
- $15.46
- 200D MA
- $22.37
- Beta
- 0.32
- RSI (14)
- 51
- Avg Volume
- 4.68M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ultragenyx used the quarter to celebrate two gene-therapy approvals, but the call was dominated by a pipeline reset, major cost cuts, and a commitment to reach profitability in 2027.· November 3, 2026
- GENGLYCOS and FAYUVI were approved in the quarter, giving Ultragenyx six approved medicines and two new gene-therapy launches.
- GTX-102 failed in Phase 3 and was discontinued; UX701 for Wilson disease was also terminated after not meeting the bar to advance.
- Management is cutting headcount by about 20% to roughly 1,000 employees and reducing R&D/SG&A to align with the new revenue base.
- 2026 revenue guidance was reaffirmed at $730 million to $760 million, excluding the new launches, with CRYSVITA at $500 million to $520 million and DOJOLVI at $100 million to $110 million.
- The company said it now has the cash needed to reach profitability without additional fundraising, helped by roughly $350 million of PRV sale proceeds.
Ultragenyx did not provide quarterly revenue or EPS figures on the call, referring investors to the press release for third-quarter financials. For 2026, management reaffirmed total revenue guidance of $730 million to $760 million, excluding FAYUVI and GENGLYCOS launches; CRYSVITA revenue of $500 million to $520 million; and DOJOLVI revenue of $100 million to $110 million. Combined 2026 R&D and SG&A are expected to be flat to down low single digits versus 2025, including about $30 million of severance and other nonrecurring restructuring charges from the first half and about $25 million expected in Q4. For 2027, the company expects R&D of less than $350 million, SG&A of less than $375 million, full-year GAAP net income profitability, and positive operating cash flow. Management also said net proceeds from two PRV sales totaled approximately $350 million after payments and fees, and said this strengthens the balance sheet enough to reach profitability without additional fundraising.
Emil Kakkis framed the quarter as both a major achievement and a reset. He emphasized the FDA approvals of GENGLYCOS and FAYUVI, calling them the result of years of work and highlighting their potential to address severe unmet need, while also acknowledging the disappointment of the GTX-102 Phase 3 miss and the termination of UX701. His tone was candid and forceful on cost discipline: he said the company is right-sizing to fit revenue, focusing on commercial execution, and positioning Ultragenyx to become a profitable, self-sustaining rare-disease company.
Howard Horn focused on the new cost structure and the path to profitability. He reaffirmed 2026 revenue guidance of $730 million to $760 million, with CRYSVITA at $500 million to $520 million and DOJOLVI at $100 million to $110 million, while keeping 2026 combined R&D and SG&A flat to down low single digits versus 2025 despite restructuring charges. For 2027, he guided to R&D below $350 million, SG&A below $375 million, GAAP net income profitability, and positive operating cash flow. He also said the company reduced headcount by about 20% to roughly 1,000 employees, and that the approximately $350 million from PRV sales means Ultragenyx should not need additional fundraising to reach profitability.
Analysts pressed on what remains in the reduced R&D budget, especially setrusumab and the OTC and gene-therapy programs. Management said setrusumab spend is included, and that any future OI trial would likely need to be enriched for patients with higher fracture risk, but they would not yet commit to a specific path or timeline with FDA. Questions also focused on FAYUVI labeling and uptake; management said payer policies to date have been positive and in line with the label, with no restrictions seen so far. For the launches, management said FAYUVI demand is urgent and patient-driven, while GENGLYCOS should ramp more methodically, and that the company will first share launch metrics like QTCs, start forms, and payer coverage before giving revenue guidance.
The biggest bull case is that Ultragenyx now has two newly approved gene therapies layered onto a still-growing commercial base, with management saying the business can reach profitability in 2027. The company also said it has enough cash after the PRV sales to get there without extra financing, while existing products like CRYSVITA, DOJOLVI, and EVKEEZA continue to show growth.
The call also showed meaningful pipeline risk: GTX-102 failed in Phase 3 and was discontinued, and UX701 was terminated after not meeting the company’s advancement threshold. Management is shrinking the workforce by about 20% and cutting R&D sharply, which underscores pressure to keep spending aligned with revenue; future growth now depends heavily on successful launches, continued uptake of existing products, and resolving the path forward for programs like setrusumab and DTX301.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.5%
- Shares Outstanding
- 101.92M
- Float Shares
- 93.25M
of shares held by institutions
329 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RARE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Sep 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 18, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 15, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 21, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 11, 22 | Filing → |
| Kurt SchraderHouse · OR05 | Buy | Aug 30, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.43M | ▲ 778.58K |
| Vanguard Group Inc | 10.26M | ▲ 131.09K |
| Vanguard Portfolio Management LLC | 8.42M | ▲ 1.63M |
| Rtw Investments, LP | 7.80M | ▲ 4.15M |
| State Street Corp | 7.54M | ▲ 1.38M |
| Aqr Capital Management LLC | 6.56M | ▲ 1.98M |
| Vanguard Capital Management LLC | 4.30M | ▲ 2.68K |
| Two Sigma Investments, LP | 3.62M | ▲ 1.42M |
| Jacobs Levy Equity Management, Inc | 2.94M | ▲ 1.51M |
| Frontier Capital Management Co LLC | 2.85M | ▲ 656.75K |
| Nantahala Capital Management, LLC | 2.34M | ▲ 2.34M |
| Gw&K Investment Management, LLC | 2.31M | ▲ 826.67K |
Held by 367 ETFs
Biggest fund positions in RARE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Horn Howard | sell | 7,066 |
| Sep 15, 26 | Huizenga Theodore Alan | sell | 1,283 |
| Sep 3, 26 | Huizenga Theodore Alan | sell | 161 |
| Aug 3, 26 | Parschauer Karah Herdman | sell | 1,900 |
| Aug 3, 26 | Horn Howard | sell | 4,696 |
| Jul 1, 26 | Horn Howard | sell | 4,698 |
| Jun 15, 26 | Sanders Corazon (Corsee) D. | sell | 2,000 |
| Jun 15, 26 | Parschauer Karah Herdman | sell | 1,899 |
| Jun 1, 26 | Horn Howard | sell | 4,653 |
| May 14, 26 | Fust Matthew K | other | 7,751 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RARE coverage
Recent articles, reports, and earnings notes.

Gene Therapy Stocks That Turn Science Into Sales: 7 Picks
A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.

Clinuvel Pharmaceuticals Limited IPO Preview: Nasdaq ADR Upgrade
Clinuvel Pharmaceuticals Limited American Depositary Shares are expected to list on NASDAQ on 2026-07-20, but the price range has not been disclosed. The setup looks more like an ADR listing upgrade than a classic new-money IPO, with an established profitable specialty pharma business behind it.
Want a deeper read on RARE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
defenseworld.net · Nov 17
Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
marketbeat.com · Nov 17
Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold
seekingalpha.com · Nov 12
Ultragenyx to Participate at Investor Conferences in London
globenewswire.com · Nov 11
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
globenewswire.com · Nov 6
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot
seekingalpha.com · Nov 4
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.